[PR]今日のﾆｭｰｽは
｢Infoseek ﾓﾊﾞｲﾙ｣
BURRELLE'S/VMS NewsAlert Service
75 East Northfield Road/ Livingston, NJ /
973-992-6600
SOURCE: PR Newswire
SUPPLIER: PR Newswire
DATE: 04/19/99
TIME: 15:34 EDT
HEADLINE: Nabi-NicVAX(TM)
Data Presented At The Society
HIGHLIGHTS: University of
Minnesota
Nabi-NicVAX(TM) Data Presented At The Society
For Research On Nicotine And Tobacco Meeting
BOCA RATON, Fla., April 19 /PRNewswire/ -- Nabi(R) (Nasdaq: NABI), in
collaboration with scientists from the University of Houston-Clear Lake and The University
of Minnesota, reported results of pre-clinical studies on
Nabi-NicVAX(TM) at the 1999 Annual Meeting of The Society for Research on
Nicotine and Tobacco (SRNT) held in San Diego, CA, March 5-7, 1999. Nabi-NicVAX
is an experimental conjugate vaccine that has been shown, in animal studies, to
generate elevated levels of high-affinity antibodies to nicotine. Nabi is
developing this vaccine for the prevention and treatment of nicotine addiction.
Dr. David Malin of the University of Houston-Clear Lake reported that purified
antibodies generated in laboratory animals in response to vaccination with
Nabi-NicVAX were able to significantly reduce brain nicotine concentrations in
rats after the intravenous administration of nicotine. The antibodies were also
reported to reduce or prevent nicotine-induced blood pressure increases in rats
in a dose-related manner. In another study, antibodies induced in response to
vaccination with Nabi-NicVAX completely prevented increases in locomotor
activity in rats in response to injected nicotine. These data demonstrate that
vaccine-induced, nicotine-specific antibodies can reduce or prevent at least
some of the pharmacokinetic, cardiovascular and behavioral consequences of
nicotine in rats. The effects were observed at nicotine doses and nicotine serum
concentrations equaling or exceeding those typically associated with nicotine
exposure in cigarette smokers.
"We are excited about the results obtained thus far with Nabi-NicVAX in
these animal models," declared Dr. Robert Naso, Sr. Vice President.
"The antibodies generated in response to vaccination with Nabi-NicVAX
appear to be preventing nicotine from reaching receptors in the brains of the
treated animals. We expect that blocking uptake of nicotine by the brain will
greatly reduce the addictive effects of nicotine. If similar effects can be
achieved in humans, we may be able to use the vaccine to prevent nicotine
addiction or to help tobacco users kick their nicotine habits."
"Research has shown that a combination of pharmacological and behavioral
treatments can more than double the odds of success for individuals who try to
quit smoking," said Dr. Alan I. Leshner, Director of the National Institute
on Drug Abuse, National Institutes of Health. "Just as with other drugs,
however, ultimately our best treatment is prevention. If the promise of the
basic research on this vaccine extends to effectiveness in humans, it may not
only help individuals trying to quit but may also prevent nicotine addiction in
at-risk individuals."
Partial funding for the scientific research conducted by Dr. David Malin and his
colleagues at the University of Houston-Clear Lake and by Dr. Paul Pentel and
his colleagues at The University of
Minnesota was provided by the National Institute on Drug Abuse,
National Institutes of Health, under grant DA10714 (PRP) and by Nabi. Detailed
findings from this research have been submitted for publication.
Tobacco use is the single-leading preventable cause of death in the United
States. It is estimated that more than 50 million Americans are current smokers
and another 6.8 million use smokeless tobacco. In the US, there are
approximately 6 million teenagers who reportedly use tobacco regularly and, even
more troubling, it is estimated that more than 100,000 adolescents under 13
years of age smoke cigarettes. On a worldwide basis, the statistics are even
more staggering as one out of three men and women over age 18 smokes.
Economically, smoking is reportedly responsible for approximately 7 percent of
total US health care costs -- estimated at $50 billion each year.
Nabi, a fully integrated biopharmaceutical company, has a broad product
portfolio and significant R&D capabilities focused on the development and
commercialization of drugs that prevent and treat infectious and autoimmune
diseases. Nabi currently has several clinical trials underway in these areas and
has three marketed pharmaceutical products. Additional information may be
obtained on the Company's website at: www.nabi.com.
This release contains forward-looking statements that involve risks and
uncertainties. The Company's actual results may differ significantly from
results discussed in the forward-looking statements, due to a number of factors,
including, but not limited to, the uncertainty of product development;
government regulations and the uncertainty of regulatory approval; and
dependence upon second parties to manufacture product. These factors are more
fully discussed in the Company's most recent Form 10-K filed with the Securities
and Exchange Commission.
Source: Nabi
-0- 04/19/99
/CONTACT: Tanina Frouge, Director, Investor Relations of Nabi, 561-989-5815/
/Web site: http://www.nabi.com/
(NABI)
CO: Nabi; University of Houston-Clear Lake; The University
of Minnesota;
1999 Annual Meeting of The Society for Research on Nicotine and Tobacco;
National Institute on Drug Abuse, National Institutes of Health ST: California,
Florida, Minnesota, Texas
IN: MTC HEA
SU: PDT
DR
-- FLM018 --
ホームページ ｜ プロフィール ｜ 研究報告リスト
筆者へのメールは kaijinhi@yahoo.co.jp
にお願いします。
このニコチンワクチンは臨床試験の研究段階です。
このページは商用目的ではありません。